Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study

BACKGROUND: Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumo, Takehiro, Tone, Mari, Kuse, Naoyuki, Awano, Nobuyasu, Tanaka, Atsuko, Jo, Tatsunori, Yoshimura, Hanako, Minami, Jonsu, Takada, Kohei, Inomata, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210162/
https://www.ncbi.nlm.nih.gov/pubmed/32395482
http://dx.doi.org/10.21037/atm.2020.04.01

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210162/
https://www.ncbi.nlm.nih.gov/pubmed/32395482
http://dx.doi.org/10.21037/atm.2020.04.01

Ejemplares similares